{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T07:19:47Z","timestamp":1771744787136,"version":"3.50.1"},"reference-count":28,"publisher":"Georg Thieme Verlag KG","issue":"10","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>\n          Abstract\n        <\/jats:title><jats:p>Immune checkpoint inhibitors are increasingly used in advanced malignant diseases and are\n      well-known for their good results. With the blockade of immune checkpoints, the probability of\n      immune-related adverse events is also increased.<\/jats:p><jats:p>We present a 54-year-old female patient with advanced NSCLC. She was treated with\n      pembrolizumab and developed a stable disease under therapy. After six cycles, she presented\n      with massive epigastric pain to our emergency department. Gastroscopy showed severe\n      erosive-fibrinous pangastritis without the involvement of the esophagus, duodenum, or other\n      immune-related adverse effects. Histology showed the complete destruction of the gastric\n      mucosa. We concluded an immune-mediated gastritis by pembrolizumab, after the exclusion of\n      other differential diagnoses.<\/jats:p><jats:p>Despite treatment with prednisolone and marked improvement of her symptoms, the mucosa was\n      never fully reconstituted into a healthy mucosa.<\/jats:p><jats:p>Furthermore, we collected published reports of similar cases and conducted a comparison\n      with features of a typical, endogenous type A gastritis to highlight similarities and\n      differences.<\/jats:p>","DOI":"10.1055\/a-2000-5705","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T23:58:36Z","timestamp":1679702316000},"page":"1385-1393","source":"Crossref","is-referenced-by-count":6,"title":["Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab \u2013 Differences and Similarities in Comparison to \u201cendogenous\u201d autoimmune Type A Gastritis and a review of literature"],"prefix":"10.1055","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7116-7957","authenticated-orcid":false,"given":"Miriam Eva","family":"Ecker","sequence":"additional","affiliation":[{"name":"Gastroenterology, Endocrinology, Diabetology and General Medicine, Klinikum Kassel GmbH, Kassel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgard","family":"Weckauf","sequence":"additional","affiliation":[{"name":"Pathology, Klinikum Kassel GmbH, Kassel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Tebbe","sequence":"additional","affiliation":[{"name":"Private Practice for Haematology and Oncology, Kassel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Schuppert","sequence":"additional","affiliation":[{"name":"Gastroenterology, Endocrinology, Diabetology and General Medicine, Klinikum Kassel GmbH, Kassel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer\n          immunotherapy","volume":"184","author":"M Dougan","year":"2021","journal-title":"Cell"},{"issue":"19","key":"ref2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung\n          Cancer","volume":"375","author":"M Reck","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"ref3","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/jcb.26005","article-title":"Targeting Immunotherapy to the Tumor Microenvironment","volume":"118","author":"M Dougan","year":"2017","journal-title":"J Cell Biochem"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2019.04.018","article-title":"Management of immune related adverse events induced by immune checkpoint\n          inhibition","volume":"456","author":"A Teufel","year":"2019","journal-title":"Cancer Letters"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1159\/000511252","article-title":"Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor\n          Therapy in a Patient with Advanced Melanoma","volume":"14","author":"M Paparoupa","year":"2020","journal-title":"Case Rep Gastroenterol"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1177\/1078155220910202","article-title":"Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors:\n          Four cases describing the clinical heterogeneity of central endocrine\n          dysfunction","volume":"26","author":"A Hartmann","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11864-018-0562-9","article-title":"Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung\n          Cancer","volume":"19","author":"B Wills","year":"2018","journal-title":"Cur Treat Options Oncol"},{"issue":"18","key":"ref8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ijms21186652","article-title":"Identification of Gastritis Subtypes by Convolutional Neuronal Networks on\n          Histological Images of Antrum and Corpus Biopsies","volume":"21","author":"G Steinbuss","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"04","key":"ref9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/den.14175","article-title":"Endoscopic features and clinical importance of autoimmune gastritis","volume":"34","author":"T Kamada","year":"2022","journal-title":"Dig Endosc"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/ajg.2009.231","article-title":"Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic\n          gastritis with respect to cobalamin deficiency","volume":"104","author":"E Lahner","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"04","key":"ref11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1055\/a-0859-1883","article-title":"Management of epithelial precancerous conditions and lesions in the stomach (MAPS\n          II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and\n          Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade\n          Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019","volume":"51","author":"P Pimentel-Nunes","year":"2019","journal-title":"Endoscopy"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1053\/j.gastro.2021.06.078","article-title":"AGA Clinical Practice Update on the Diagnosis and Management of Atrophic\n          Gastritis: Expert Review","volume":"161","author":"SC Shah","year":"2021","journal-title":"Gastroenterology"},{"issue":"02","key":"ref14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12328-021-01582-5","article-title":"Temporal observation of endoscopic and histological findings of gastritis after\n          administration of an immune checkpoint inhibitor: a case report","volume":"15","author":"K Saito","year":"2022","journal-title":"Clin J Gastroenterol"},{"issue":"10","key":"ref15","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1111\/jgh.15427","article-title":"Gastrointestinal: Severe gastritis with complete gastric mucosal\n          sloughing","volume":"36","author":"R Nasser","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"06","key":"ref16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/jcu.22975","article-title":"A case of immune checkpoint inhibitor- associated gastroenteritis detected by\n          ultrasonography","volume":"49","author":"S Omotehara","year":"2021","journal-title":"J Clin Ultrasound"},{"issue":"03","key":"ref17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/jgh.15248","article-title":"Gastrointestinal: Recurrence of pembrolizumab- induced severe gastritis after\n          tapering steroid therapy","volume":"36","author":"Y Okubo","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"03","key":"ref18","first-page":"482","article-title":"Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma\n          patient","volume":"83","author":"J Vandepapeli\u00e8re","year":"2020","journal-title":"Acta Gastroenterol Belg"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.3747\/co.27.6163","article-title":"Severe cytomegalovirus gastritis after pembrolizumab in a patient with\n          melanoma","volume":"27","author":"H Kim","year":"2020","journal-title":"Curr Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2022.02.010","article-title":"Delayed hemorrhagic gastritis caused by immunotherapy in a patient With metastatic\n          melanoma","author":"M Elmasry","year":"2022","journal-title":"Am J Med Sci"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"S891","DOI":"10.1016\/S0016-5085(17)33042-1","article-title":"First Reported Case of Pembrolizumab-Induced Immune Mediated Hemorrhagic\n          Gastritis","volume":"52","author":"B Cinnor","year":"2017","journal-title":"Gastroenterology"},{"issue":"01","key":"ref22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/jpgm.JPGM_1132_20","article-title":"Unusual severe gastritis and gastric ulcers caused by pembrolizumab","volume":"68","author":"WT Liu","year":"2022","journal-title":"Journal Postgrad Med"},{"issue":"02","key":"ref23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41395-018-0366-3","article-title":"Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab","volume":"114","author":"BB Rao","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.32074\/1591-951X-24-19","article-title":"Immune-related acute and lymphocytic gastritis in a patient with metastatic\n          melanoma treated with pembrolizumab immunotherapy","volume":"111","author":"P Gaffuri","year":"2019","journal-title":"Pathologica"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/CMR.0000000000000502","article-title":"Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic\n          melanoma","volume":"28","author":"RHL Yip","year":"2018","journal-title":"Melanoma Res"},{"issue":"05","key":"ref26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.14740\/gr1068w","article-title":"An Unusual Case of Gastritis in One Patient Receiving PD-1 Blocking Therapy:\n          Coexisting Immune-Related Gastritis and Cytomegaloviral Infection","volume":"11","author":"J Lu","year":"2018","journal-title":"Gastroenterol Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000509196","article-title":"Checkpoint Inhibitor-Induced Gastroduodenitis: An Unusual Manifestation","author":"R Mendo","year":"2021","journal-title":"GE Port J Gastroenterol"},{"issue":"05","key":"ref28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.biochi.2013.02.008","article-title":"Diagnosis and management of clinical and subclinical cobalamin deficiencies: why\n          controversies persist in the age of sensitive metabolic testing","volume":"95","author":"R Carmel","year":"2013","journal-title":"Biochimie"},{"issue":"03","key":"ref29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5582\/ddt.2019.01032","article-title":"Rapid temporal improvement of pembrolizumab-induced pneumonitis using the\n          anti-TNF-alpha antibody infliximab","volume":"13","author":"Y Sawai","year":"2019","journal-title":"Drug Discov Ther"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2000-5705.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T23:43:57Z","timestamp":1696895037000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2000-5705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,9]]},"published-print":{"date-parts":[[2023,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2000-5705","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]}}}